Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Helicobacter & Campylobacter May Play Roles in IBD

Reuters Staff  |  November 9, 2015

NEW YORK (Reuters Health)—Helicobacter and Campylobacter species appear to play opposing roles in inflammatory bowel disease (IBD), according to a systematic review and meta-analysis.

The prevalence of IBD has increased steadily in the face of falling H. pylori infection rates, suggesting a negative association, whereas some studies have suggested that some Campylobacter species are involved in the pathogenesis of IBD.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Hazel M. Mitchell from The University of New South Wales in Sydney, Australia, and colleagues investigated the possible association between H. pylori, Helicobacter enterohepatic species (EHS), and Campylobacter and IBD in a review of 64 published studies (40 for H. pylori, 15 for Helicobacter EHS and nice for Campylobacter).

There was a consistent negative association between gastric H. pylori and IBD, with H. pylori appearing to reduce the odds of Crohn’s disease by 62%, of ulcerative colitis by 47%, and unclassified IBD by 57%.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

These significant inverse associations persisted regardless of age, ethnicity and detection techniques, the researchers report in Gut, online Oct. 27.

Medications commonly used to treat IBD did not influence the negative association between H. pylori and IBD, but antibiotics appeared to amplify the negative association.

Helicobacter EHS, however, was associated with a borderline increase in IBD prevalence, and the association became significant when H. pylori was excluded from the analysis. There was a 2.62-fold increase in the odds of IBD in the presence of non-H. pylori EHS.

Campylobacter species were associated with a 2.97-fold increase in the odds of IBD, mainly due to C. concisus and C. showae.

“The results obtained by the current meta-analysis provide insights into the true direction of the association between H. pylori infection and IBD,” the researchers conclude. “If H. pylori infection indeed protects against IBD, selective treatment and surveillance of individuals at high risk of developing serious H. pylori-related gastric pathologies would be more relevant than a population-wide eradication approach, which has currently been proposed in some Asian countries.”

Dr. Mitchell did not respond to a request for comment.

Share: 

Filed under:ConditionsOther Rheumatic Conditions Tagged with:H. pyloriinflammatory bowel disease

Related Articles

    Gut Feeling: A Comprehensive Look at the Pathogenesis, Management & Treatment of Inflammatory Bowel Disease

    May 24, 2021

    Patients with autoimmune diseases, such as spondyloarthritis, are at risk of developing inflammatory bowel disease. Here are considerations for its management and treatment.

    Case Report: Possible Overlapping Vasculitis & Ulcerative Colitis

    January 17, 2020

    A 42-year-old man with a history of ulcerative colitis (UC), primary sclerosing cholangitis (PSC) and chronic sinusitis was referred to a rheumatologist to evaluate for a possible diagnosis of systemic vasculitis. This patient had developed new skin lesions, gingival hypertrophy and ulcerating tracheobronchitis, concerning for possible granulomatosis with polyangiitis (GPA). Since 1994, the patient had…

    Volatility of the Gut Microbiome Tied to IBD

    February 21, 2017

    NEW YORK (Reuters Health)—Fluctuations in the gut microbiome over time could underlie inflammatory bowel disease (IBD), including Crohn’s and ulcerative colitis, researchers suggest. “Both the state and the dynamics of the human gut microbiome in healthy individuals are highly personalized. Although cross-sectional studies have revealed dysbiosis of the gut microbiome in IBD, little is known…

    Rheuminations: Road to Success in Medicine May Be Paved with Failure

    February 1, 2014

    How healthcare has benefited from breakthrough discoveries related to bovine spongiform encephalitis, H. pylori ulcer disease, and properdin by researchers who persevered despite criticism from skeptics

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences